Abdul Abdellatif1
Brad A. Marder
John D. Scandling
95% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
- 1Department of Medicine, Division of Nephrology at CLS Health and Baylor College of Medicine, Houston, TX, United States
- 2Rare Disease Unit, Amgen Inc. (formerly Horizon Therapeutics), Thousand Oaks, CA, United States
- 3Division of Nephrology, Stanford School of Medicine, Stanford, CA, United States
by Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025). Front. Immunol. 16:1516146. doi: 10.3389/fimmu.2025.1516146
In the published article, the reference for “The high impact of gout on lowering patient QOL is well established, and these effects are more pronounced in KT recipients” was incorrectly written as “40”. It should be “14”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: gout, kidney transplant, urate, quality of life, renal function, blood pressure
Citation: Abdellatif A, Zhao L, Obermeyer K, Vranic Z, Marder BA and Scandling JD (2025) Corrigendum: Quality of life improvements and clinical assessments in kidney transplant recipients undergoing pegloticase treatment for uncontrolled gout: findings of the phase 4 PROTECT clinical trial. Front. Immunol. 16:1595951. doi: 10.3389/fimmu.2025.1595951
Received: 18 March 2025; Accepted: 25 March 2025;
Published: 03 April 2025.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2025 Abdellatif, Zhao, Obermeyer, Vranic, Marder and Scandling. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Brad A. Marder, Ym1hcmRlckBhbWdlbi5jb20=